LianBio Enters Into Agreement With Janssen Pharmaceutical, Assigns NBTXR3 Rights In China And Other Asian Markets For $25M
Portfolio Pulse from Benzinga Newsdesk
LianBio has assigned its exclusive rights to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand to Janssen, a Johnson & Johnson company. The deal includes a one-time payment of $25 million to LianBio, with an additional sales milestone payment of $5 million possible. LianBio will assist in transitioning the asset to Janssen for up to six months.
December 26, 2023 | 7:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson's Janssen acquires rights to NBTXR3 in key Asian markets, potentially expanding its oncology portfolio. The financial impact is likely minimal relative to J&J's overall business size.
While the acquisition of NBTXR3 rights could enhance Janssen's product pipeline, the $25 million payment is relatively small compared to Johnson & Johnson's overall financial scale, likely resulting in a neutral short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 30
RELEVANCE 70
POSITIVE IMPACT
LianBio receives $25M from Janssen for rights to NBTXR3 in select Asian markets, with potential for an additional $5M. This deal could bolster LianBio's financial position and fund further development.
The agreement provides LianBio with a significant one-time payment, which is likely to have a positive impact on the company's financials and investor sentiment in the short term. The potential for an additional sales milestone payment adds further upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100